Literature DB >> 32271583

Surface Modification Using Ultraviolet-Ozone Treatment Enhances Acute Drug Transfer in Drug-Coated Balloon Therapy.

Dara Azar, Jared T Lott, Ehsan Jabbarzadeh, Tarek Shazly, Vijaya B Kolachalama1,2.   

Abstract

Endovascular deployment of drug-coated balloons (DCB) is an emerging strategy for the revascularization of arterial disease. Randomized clinical trials have demonstrated DCB effectiveness, but a recent meta-analysis reported increased mortality risk in humans with use of DCBs containing the common antiproliferative drug paclitaxel. While many factors could have contributed to adverse outcomes, current DCB designs have poor drug delivery efficiency, risk of systemic toxicity, and limited potential to retain therapeutic drug concentrations within the arterial wall following the procedure. Our study focuses on developing a strategy to enhance acute drug transfer from the balloon to the arterial wall over the short procedural window (∼30-120 s). We employed ultraviolet-ozone plasma (UVO) treatment to increase the hydrophilicity of a prototypical balloon material (Nylon-12) and subsequently applied a urea-paclitaxel coating previously shown to undergo favorable adhesive interactions with the arterial wall under simulated ex-vivo deployment. A series of assays were performed to characterize our experimental DCBs in terms of UVO-induced alterations in balloon surface hydrophobicity, formed coating microstructure, coating stability, and acute drug transfer to the arterial wall. Obtained results suggest that the UVO-based surface modification of angioplasty balloons is a promising design strategy and highlights the critical role of coating microstructure in determining the drug transfer efficiency in DCB therapy.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32271583      PMCID: PMC9337626          DOI: 10.1021/acs.langmuir.0c00298

Source DB:  PubMed          Journal:  Langmuir        ISSN: 0743-7463            Impact factor:   4.331


  20 in total

1.  The LEVANT I (Lutonix paclitaxel-coated balloon for the prevention of femoropopliteal restenosis) trial for femoropopliteal revascularization: first-in-human randomized trial of low-dose drug-coated balloon versus uncoated balloon angioplasty.

Authors:  Dierk Scheinert; Stephan Duda; Thomas Zeller; Hans Krankenberg; Jens Ricke; Marc Bosiers; Gunnar Tepe; Scott Naisbitt; Kenneth Rosenfield
Journal:  JACC Cardiovasc Interv       Date:  2014-01       Impact factor: 11.195

2.  Drug-coated balloons--the importance of packing and dosing antiproliferative drugs.

Authors:  Christoph Hehrlein
Journal:  Catheter Cardiovasc Interv       Date:  2015-08       Impact factor: 2.692

3.  Optimization of balloon coating process for paclitaxel coated balloons via micro-pipetting method.

Authors:  Steven E Woolford; Mandy Tran; Agnes NguyenPho; Martin K McDermott; Berk Oktem; Samanthi Wickramasekara
Journal:  Int J Pharm       Date:  2018-11-02       Impact factor: 5.875

4.  Drug-coated balloon for treatment of de-novo coronary artery lesions in patients with high bleeding risk (DEBUT): a single-blind, randomised, non-inferiority trial.

Authors:  Tuomas T Rissanen; Sanna Uskela; Jaakko Eränen; Pirjo Mäntylä; Annika Olli; Hannu Romppanen; Antti Siljander; Mikko Pietilä; Mikko J Minkkinen; Jerry Tervo; Jussi M Kärkkäinen
Journal:  Lancet       Date:  2019-06-13       Impact factor: 79.321

5.  Surface modification of polyethylene balloon catheters for local drug delivery.

Authors:  T Richey; H Iwata; H Oowaki; E Uchida; S Matsuda; Y Ikada
Journal:  Biomaterials       Date:  2000-05       Impact factor: 12.479

6.  Mechanisms of tissue uptake and retention in zotarolimus-coated balloon therapy.

Authors:  Vijaya B Kolachalama; Stephen D Pacetti; Joseph W Franses; John J Stankus; Hugh Q Zhao; Tarek Shazly; Alexander Nikanorov; Lewis B Schwartz; Abraham R Tzafriri; Elazer R Edelman
Journal:  Circulation       Date:  2013-04-12       Impact factor: 29.690

7.  Risk of Death Following Application of Paclitaxel-Coated Balloons and Stents in the Femoropopliteal Artery of the Leg: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Authors:  Konstantinos Katsanos; Stavros Spiliopoulos; Panagiotis Kitrou; Miltiadis Krokidis; Dimitrios Karnabatidis
Journal:  J Am Heart Assoc       Date:  2018-12-18       Impact factor: 5.501

8.  Intrinsic coating morphology modulates acute drug transfer in drug-coated balloon therapy.

Authors:  Gary H Chang; Dara A Azar; Chimera Lyle; Vipul C Chitalia; Tarek Shazly; Vijaya B Kolachalama
Journal:  Sci Rep       Date:  2019-05-02       Impact factor: 4.996

9.  Paclitaxel-coated balloon angioplasty vs. drug-eluting stenting for the treatment of coronary in-stent restenosis: a comprehensive, collaborative, individual patient data meta-analysis of 10 randomized clinical trials (DAEDALUS study).

Authors:  Daniele Giacoppo; Fernando Alfonso; Bo Xu; Bimmer E P M Claessen; Tom Adriaenssens; Christoph Jensen; María J Pérez-Vizcayno; Do-Yoon Kang; Ralf Degenhardt; Leos Pleva; Jan Baan; Javier Cuesta; Duk-Woo Park; Heribert Schunkert; Roisin Colleran; Pavel Kukla; Pilar Jiménez-Quevedo; Martin Unverdorben; Runlin Gao; Christoph K Naber; Seung-Jung Park; José P S Henriques; Adnan Kastrati; Robert A Byrne
Journal:  Eur Heart J       Date:  2020-10-07       Impact factor: 29.983

10.  Dextran sulfate as a drug delivery platform for drug-coated balloons: Preparation, characterization, in vitro drug elution, and smooth muscle cell response.

Authors:  Sujan Lamichhane; Jordan Anderson; Tyler Remund; Patrick Kelly; Gopinath Mani
Journal:  J Biomed Mater Res B Appl Biomater       Date:  2015-07-31       Impact factor: 3.368

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.